Zoetis Faces Multiple Securities Class Actions Over Alleged Non‑Disclosure on Pet Drugs
Plaintiff firms say Zoetis failed to disclose specific safety and competitive problems that later produced sharp drops in its stock.
Overview
- In early June several plaintiff law firms publicly announced securities complaints against Zoetis and are soliciting investors to join the class.
- The complaints say Zoetis made false or misleading statements about demand and vet adoption for companion‑animal medicines including Librela, Apoquel, Cytopoint, and Simparica Trio.
- Plaintiffs tie the class period to January 14, 2025 through May 6, 2026 and set a July 27, 2026 deadline for investors to seek lead‑plaintiff status.
- Firms point to four corrective disclosures between August 2025 and May 2026 that they say revealed product and competitive problems and drove Zoetis shares from $151.81 to $87.31.
- The next steps are competing lead‑plaintiff filings, possible consolidation of complaints, and anticipated defendant motions to dismiss, and investors should note these are allegations pending court resolution that could affect recoveries and company legal exposure.